Provided by Tiger Trade Technology Pte. Ltd.

Viatris Inc.

16.38
-0.1200-0.73%
Pre-market: 16.530.1500+0.92%04:01 EDT
Volume:9.01M
Turnover:147.17M
Market Cap:18.82B
PE:-46.23
High:16.51
Open:16.50
Low:16.15
Close:16.50
52wk High:18.39
52wk Low:9.43
Shares:1.15B
Float Shares:1.14B
Volume Ratio:1.39
T/O Rate:0.79%
Dividend:0.48
Dividend Rate:2.93%
EPS(TTM):-0.3543
EPS(LYR):-3.0024
ROE:-2.75%
ROA:2.67%
PB:1.32
PE(LYR):-5.46

Loading ...

Barclays Keeps Their Buy Rating on Viatris (VTRS)

TIPRANKS
·
Apr 13

Assessing Viatris (VTRS) Valuation After A Recent Share Price Pullback

Simply Wall St.
·
Apr 11

Viatris Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Apr 11

Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting

Reuters
·
Apr 10

The Stories Behind the Market's 10 Cheapest Stocks -- and Which One Looks Best -- Barrons.com

Dow Jones
·
Apr 10

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
Apr 08

How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story

Simply Wall St.
·
Apr 06

Viatris (VTRS) Valuation In Focus After MR-139 Phase III Failure And Pipeline Setback

Simply Wall St.
·
Apr 03

Viatris Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Apr 03

Viatris Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Apr 01

Theravance, Viatris settle Yupelri patent suit, allow Mankind generic launch in 2039

Reuters
·
Mar 31

Viatris Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Mar 28

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Viatris Chief Accounting Officer Paul Campbell disposes of USD 283,000 in common shares

Reuters
·
Mar 25

Viatris Is Maintained at Overweight by Barclays

Dow Jones
·
Mar 24

Viatris Inc. : Barclays Raises Target Price to $17 From $15

THOMSON REUTERS
·
Mar 24

Viatris price target raised to $17 from $15 at Barclays

TIPRANKS
·
Mar 24

Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS)

TIPRANKS
·
Mar 24

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Reuters
·
Mar 24

Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating

MT Newswires Live
·
Mar 23